Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

gargoyl Dec. 5 at 5:29 AM

$BLRX I’ll just nonchalantly (never wrote the word down before) put this H👂

0 · Reply

Love_To_Learn Dec. 4 at 1:07 PM

hmmmmmmm maybe blrx can b of service for the next week and their movement yes $BLRX need your wedge as well to merge with capr wedge from years ago work that 36-40 pt later and 2.56 for markets !

0 · Reply

Raspring81 Dec. 3 at 9:36 PM

$BLRX Israeli scam stock

0 · Reply

tankwfwf Dec. 2 at 11:15 PM

$BLRX what happened to Stealing your thunder and imabean. Let us know how you guys knew when to quit pumping and got out. Shame you didn't let us into how you knew Phil and aphexda were just pie in the sky. You fellows pulled out as soon as the drug was approved. Stealing your thunder did the same smoke and mirrors with dare bio.

0 · Reply

Flowjob Dec. 1 at 5:30 PM

$BLRX no mention about the SCD data in the recent ER lol

1 · Reply

aletz Nov. 27 at 7:11 PM

$BLRX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ On this week's AI scanner result

0 · Reply

ZacksSCR Nov. 25 at 8:10 PM

$BLRX: Stem Cell Mobilization Presentation at ASH https://buff.ly/l1XSHhT

0 · Reply

gargoyl Nov. 25 at 6:20 PM

$BLRX Don’t try figuring it out, just enjoy the journey.. $XBI Long the 🦋

0 · Reply

kshonstocks Nov. 25 at 3:49 PM

keep an eye on $BLRX its getting volume 50-Day Avg. Volume 35,500 BLRX per ibd

0 · Reply

gargoyl Nov. 25 at 3:45 PM

$BLRX my brother is here, he sees things, patterns, algorithms behind the perception of the standards, divergent moves with chaotic outcomes that only make sense in the after math. He said we pop here .. the chart can’t hold its pattern on the lower graph, it must climb to fulfill its proper course. He is 13, special, kinda like a savant. $XBI Long the 🦋

0 · Reply

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

Nov 24, 2025, 7:00 AM EST - 11 days ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 18, 2025, 7:00 AM EST - 17 days ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Nov 17, 2025, 7:00 AM EST - 18 days ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Sep 29, 2025, 3:27 PM EDT - 2 months ago

BioLineRx Ltd. - Special Call

Sep 29, 2025, 7:00 AM EDT - 2 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Aug 14, 2025, 10:44 AM EDT - 4 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 4 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 4 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

May 30, 2025, 1:58 PM EDT - 6 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 6 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 6 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 6 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 7 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 8 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 8 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 9 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 11 months ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 11 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 11 months ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 11 months ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

gargoyl Dec. 5 at 5:29 AM

$BLRX I’ll just nonchalantly (never wrote the word down before) put this H👂

0 · Reply

Love_To_Learn Dec. 4 at 1:07 PM

hmmmmmmm maybe blrx can b of service for the next week and their movement yes $BLRX need your wedge as well to merge with capr wedge from years ago work that 36-40 pt later and 2.56 for markets !

0 · Reply

Raspring81 Dec. 3 at 9:36 PM

$BLRX Israeli scam stock

0 · Reply

tankwfwf Dec. 2 at 11:15 PM

0 · Reply

Flowjob Dec. 1 at 5:30 PM

$BLRX no mention about the SCD data in the recent ER lol

1 · Reply

aletz Nov. 27 at 7:11 PM

$BLRX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ On this week's AI scanner result

0 · Reply

ZacksSCR Nov. 25 at 8:10 PM

$BLRX: Stem Cell Mobilization Presentation at ASH https://buff.ly/l1XSHhT

0 · Reply

gargoyl Nov. 25 at 6:20 PM

$BLRX Don’t try figuring it out, just enjoy the journey.. $XBI Long the 🦋

0 · Reply

kshonstocks Nov. 25 at 3:49 PM

keep an eye on $BLRX its getting volume 50-Day Avg. Volume 35,500 BLRX per ibd

0 · Reply

gargoyl Nov. 25 at 3:45 PM

0 · Reply

DanishViking92 Nov. 25 at 2:03 PM

$BLRX will it triple by year end?

1 · Reply

rapidtrades Nov. 24 at 8:36 PM

$BLRX

0 · Reply

rapidtrades Nov. 24 at 6:56 PM

$BLRX adding more

0 · Reply

EquityResearchCheatSheet Nov. 24 at 4:13 PM

$BLRX 3Q25 - Clinical stage, asymetric bet. Bull case $12 Bear case $2.50 https://open.substack.com/pub/richiericheps/p/blrx-3q25-clinical-stage-asymetric?r=b9ngl&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

0 · Reply

rapidtrades Nov. 24 at 3:38 PM

$BLRX

1 · Reply

OpenOutcrier Nov. 24 at 1:36 PM

$BLRX (+6.5% pre) BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update https://ooc.bz/l/85554

0 · Reply

TwongStocks Nov. 24 at 1:21 PM

$BLRX SEC filing for Q3 financials https://mayafiles.tase.co.il/rpdf/1704001-1705000/P1704639-00.pdf Some items not disclosed in the PR: • Confirmed 88,672 shares issued under the ATM in Q3, for net proceeds of approx $300K. Under General Instruction I.B.5 to Form F-3, they currently have up to $4.5 million remaining under the ATM. • 4,351,357 ADS outstanding as of Sept 30 • No update regarding their arbitration proceedings with Biokine. Biokine is seeking $7.2M in damages. • Gloria still has not initiated any of their trials in China.

1 · Reply

TwongStocks Nov. 24 at 12:05 PM

$BLRX Q3 financial results and corporate update https://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302624413.html • Conference call scheduled this morning at 8:30am ET • $25.2M as of Sept 30, cash runway into 1H 2027 • Ayrmid reported Aphexda sales of $2.4M in Q3. BLRX received royalties of $427K. Q3 royalty is higher compared to Q2 ($304K from $1.7M in Q2 revenue). • 2025 Aphexda Q1-Q3 royalty income $986K. • Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026

0 · Reply

rapidtrades Nov. 22 at 9:39 PM

$BLRX if the feds give a rate cut this can explode to over $6 range

0 · Reply

rapidtrades Nov. 21 at 8:54 PM

$BLRX

0 · Reply

rapidtrades Nov. 21 at 8:03 PM

$BLRX ok folks joined the party

0 · Reply

rapidtrades Nov. 21 at 3:23 PM

$BLRX if it has a good reporting coming monday, it can move between 20-$35.00 projection price based on past trends

2 · Reply

Market Cap	13.92M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-31.86%
Debt to Equity Ratio	0.52

Volume	6,398
Avg Vol	37,208
Day's Range	N/A - N/A
Shares Out	4.35M
Stochastic %K	14%
Beta	1.29
Analysts	Strong Sell
Price Target	$26.00